SCHEMBL29323764

SCHEMBL29323764

CCN(CC)c1ccc(C=C2C(=O)NC(=S)NC2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 1.00
KMT2A Q03164 8/20 1.00
ALDH1A1 P00352 7/20 1.00
MAPT P10636 5/20 1.00
LMNA P02545 3/20 1.00
NPSR1 Q6W5P4 3/20 1.00
TDP1 Q9NUW8 2/20 1.00
KDM4E B2RXH2 1/20 1.00
GAA P10253 1/20 1.00
MAPK1 P28482 1/20 1.00
NTSR1 P30989 1/20 1.00
CRHBP P24387 2/20 0.60
CRHR2 Q13324 2/20 0.60
GSK3B P49841 1/20 0.58
METAP1 P53582 2/20 0.58
SIRT2 Q8IXJ6 3/20 0.57
SIRT1 Q96EB6 2/20 0.57
SIRT5 Q9NXA8 2/20 0.57
RET P07949 1/20 0.57
SIRT3 Q9NTG7 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10095181 0.88 MEN1 (0.78) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL14281294 0.84 MEN1 (0.71) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL4037782 0.83 METAP1 (0.76) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL8022041 0.82 MAPK1 (0.70) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL14306896 0.82 MEN1 (0.68) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL10134156 0.80 SIRT2 (0.69) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL14680296 0.79 KMT2A (0.64) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL16712246 0.77 MAPK1 (0.63) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL6001142 0.77 PDGFRB (0.73) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL10095183 0.76 METAP1 (0.65) MEN1KMT2AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238264-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF DISARM THERAPEUTICS, INC. 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238264-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF SARM1, NADK, NNMT MEN1 3371/4885KMT2A 2098/4885ALDH1A1 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.